Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

This study has been terminated.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Maysa Abu-Khalaf, Yale University
ClinicalTrials.gov Identifier:
NCT00337376
First received: June 13, 2006
Last updated: January 13, 2014
Last verified: January 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2010
  Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)